Search results
Vladimir MOISEYENKO | Cited by 9,668 | of National Cancer Institute Thailand, Bangkok (NCI) | Read 112 publications | Contact Vladimir MOISEYENKO
- Vladimir Moiseyenko's research while affiliated with Saint Petersburg ...
Vladimir Moiseyenko's 57 research works with 1,764 citations...
- Drug therapy for hereditary cancers - ResearchGate
Evgeny N Imyanitov1,2,3*and Vladimir M Moiseyenko2....
- Vladimir Moiseyenko's research while affiliated with Saint Petersburg ...
Vladimir Moiseenko was born on 7 March 1963 in Magnitogorsk, Chelyabinsk Oblast, Russian SFSR, USSR [now Russia]. He was a writer, known for The Return (2003), 12 (2007) and Antidur (2007).
- Writer
- March 7, 1963
- Vladimir Moiseenko
- March 22, 2011
Jun 20, 2021 · Equivalent efficacy was demonstrated for the biosimilar CT-P6 and trastuzumab following neoadjuvant therapy for patients with human epidermal growth factor receptor-2 (HER2)-positive early breast cancer. Following adjuvant treatment, efficacy and safety were comparable between treatments.
- Justin Stebbing, Yauheni V. Baranau, Valery Baryash, Alexey Manikhas, Vladimir Moiseyenko, Giorgi Dz...
- 10.1007/s10549-021-06240-5
- 2021
- 2021
Dec 14, 2015 · PMID: 26668251. A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel. Oleg Gladkov, a Vladimir Moiseyenko, b Igor N. Bondarenko, c Yaroslav Shparyk, d Steve Barash, e Liat Adar, f and Noa Avisar f.
- Oleg Gladkov, Vladimir Moiseyenko, Igor N. Bondarenko, Yaroslav Shparyk, Steve Barash, Liat Adar, No...
- 10.1634/theoncologist.2015-0152
- 2016
- Oncologist. 2016 Jan; 21(1): 7-15.
Oct 22, 2022 · Abstract. MET-driven tumors are a heterogenous group of non-small cell lung cancers (NSCLC) with activating mutations. Pathologic activation of MET can be achieved with increased number of gene copies overexpression, or decreased protein degradation through several mechanisms, including mutations, amplifications, or fusions.
Vladimir Moiseyenko's 57 research works with 1,764 citations and 5,641 reads, including: A phase 1b study of the allosteric extracellular FGFR2 inhibitor alofanib in patients with pretreated ...
Evgeny N Imyanitov1,2,3*and Vladimir M Moiseyenko2. Abstract. Tumors arising in patients with hereditary cancer syndromes may have distinct drug sensitivity as compared to their sporadic...
